{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$4.96 vs. cons $4.84",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$111.2B vs. cons $110.7B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Medical care ratio",
      "prediction": "IN-LINE",
      "answer": "pred ~88.1% vs. cons 88.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$18.75 vs. cons $18.32 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Medical care ratio guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~88.5% vs. cons 88.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Implied adjusted EPS",
      "prediction": "BETTER",
      "answer": "guide ~$6.57 vs. cons $6.25 (H2 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 3.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A ~$0.43 FY2026 guide advantage and implied H2 adjusted EPS of ~$6.57 versus ~$6.25 consensus should drive positive revisions beyond the quarterly beat, supporting follow-through rather than a fade.",
  "day5_confidence": "MEDIUM"
}